<DOC>
	<DOCNO>NCT00103207</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . PURPOSE : This phase II trial study well cetuximab work treat patient recurrent stage IIIB stage IV lung cancer .</brief_summary>
	<brief_title>Cetuximab Treating Patients With Recurrent Stage IIIB Stage IV Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response rate patient recurrent stage IIIB IV bronchoalveolar carcinoma ( BAC ) adenocarcinoma lung BAC feature treat cetuximab . Secondary - Determine overall survival time progression patient treat drug . - Determine toxic effect drug patient . - Correlate expression total phosphorylated epidermal growth factor receptor ( EGFR ) , total phosphorylated AKT3 , total phosphorylated MAPKinase response patient treated drug . - Determine whether presence polymorphism mutation EGFR gene influence response patient treated drug . OUTLINE : This multicenter study . Patients receive cetuximab IV 1-2 hour day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year . ACTUAL ACCRUAL : A total 72 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma , Bronchiolo-Alveolar</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>INCLUSION CRITERIA : Histologically cytologically confirm bronchoalveolar carcinoma ( BAC ) adenocarcinoma lung BAC feature meet 1 follow stage criterion : Stage IIIB disease ( pleural pericardial effusion ) Stage IV disease Recurrent disease Measurable disease Tumor tissue available biopsy Age 18 ECOG performance status 02 Life expectancy great 3 month White blood cell ( WBC ) ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin normal Aspartate aminotransferase ( AST ) and/or alanine aminotranferease ( ALT ) ≤ 2.5 time upper limit normal Creatinine normal OR Creatinine clearance ≥ 60 mL/min No 1 prior chemotherapy regimen advance BAC More 3 year since prior chemotherapy malignancy At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) malignancy recover HIVpositive patient eligible provide follow criterion meet : CD4 count ≥ 100/mm^3 Undetectable viral load within past 3 month Receiving stable antiretroviral regimen ≥ 4 week study entry Fertile patient must use effective contraception At least 2 week since prior radiotherapy recover EXCLUSION CRITERIA : Untreated brain metastasis Patients stable brain metastasis ≥ 4 week external beam radiotherapy brain eligible Acute hepatitis Symptomatic congestive heart failure Uncontrolled hypertension Unstable angina pectoris Cardiac arrhythmia Pregnant nursing Prior allergic reaction chimerized murine monoclonal antibody therapy Documented presence human antimouse antibody Ongoing active infection Psychiatric illness social situation would preclude study compliance Other uncontrolled illness Prior cetuximab Concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) Other prior know epidermal growth factor receptor inhibitor ( e.g. , gefitinib erlotinib ) Other concurrent investigational agent Other concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>bronchioalveolar carcinoma ( BAC )</keyword>
	<keyword>adenocarcinoma BAC feature</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>cetuximab</keyword>
</DOC>